EIM
GBT

Essex Investment Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Essex Investment Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,825
Closed -$525K – 550
2018
Q3 		$525K Sell
13,825
-12,712
-48% -$563K 0.06% 292
2018
Q2 		$1.2M Buy
26,537
+17,507
+194% +$797K 0.15% 201
2018
Q1 		$436K Buy
+9,030
New +$504K 0.06% 276

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essex Investment Management's GBT Position: Q4 2018 in Review

Essex Investment Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2018, closing a stake of 13,825 shares — an estimated $525K sold.

Essex Investment Management first reported a position in GBT in Q1 2018 and held it in 3 quarters. The position peaked at $1.2M in Q2 2018. 190 funds tracked by Wall St. Rank hold GBT as of Q4 2018.

  • Essex Investment Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Essex Investment Management sold 13,825 Global Blood Therapeutics, Inc. shares in Q4 2018, an estimated $525K.
  • Essex Investment Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 3 quarters.
  • Essex Investment Management's Global Blood Therapeutics, Inc. position peaked at $1.2M in Q2 2018.
  • 190 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2018.

Based on Essex Investment Management's 13F filing for Q4 2018, filed 6 Feb 2019.